SEC Form 4 · accession 0001209191-16-156269
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Mendlein
Officer — CEO and Director · Director
Period of report
Dec 19, 2016
Accepted (ET)
Dec 21, 2016 · 11:54 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 19, 2016 | P | 69,000 | $2.198 | A | 324,971 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average price for the shares. The shares were purchased at prices ranging from $2.125 to $2.25 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
- F2Includes 2,500 shares acquired under the Company's 2015 Employee Stock Purchase Plan ("ESPP") on May 15, 2016 and 2,500 shares acquired under the ESPP on November 15, 2016.